Related Experiment Video
Updated: Feb 4, 2026

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines
Ali Alsuraifi1,2, Paul Kong Thoo Lin3, Anthony Curtis4
1Institute of Science and Technology in Medicine, Keele University, Keele ST5 5BG, UK. a.t.y.alsuraifi@keele.ac.uk.
Abstract:
Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity. The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL-1 and 2.4 mg mL-1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 μg mL-1.
Insights
This study developed a novel polymer carrier for pancreatic cancer therapy, enhancing drug delivery and effectiveness. The new system significantly boosted the cancer-killing ability of tested drugs in BxPC-3 cells.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Cancer Therapeutics
Background:
- Pancreatic tumors exhibit dense structures, leading to multidrug resistance.
- Novel drug delivery systems are crucial for overcoming resistance in cancer therapy.
- Bisnaphthalimide compounds show promise as anticancer agents.
Purpose of the Study:
- To design and synthesize a poly(allylamine)-based amphiphile for enhanced drug delivery.
- To evaluate the polymer's potential to encapsulate and solubilize poorly soluble anticancer drugs.
- To assess the carrier's efficacy in enhancing drug cytotoxicity against pancreatic cancer cells.
Main Methods:
- Synthesis of a poly(allylamine)-based amphiphile with naphthalimide groups.
- Formulation of 5-fluorouracil and a bis-naphthalimide drug within the polymer carrier.
- In vitro evaluation of drug-loaded carrier cytotoxicity in BxPC-3 pancreatic cancer cells.
Main Results:
- The novel polymer effectively encapsulated insoluble drugs at concentrations up to 4.3 mg/mL (5-fluorouracil) and 2.4 mg/mL (bis-naphthalimide).
- The poly(allylamine)-naphthalimide carrier significantly amplified the cytotoxic effect of the drugs.
- A 50% reduction in BxPC-3 cell population was achieved at a low carrier concentration of 3 μg/mL.
Conclusions:
- The developed poly(allylamine)-naphthalimide amphiphile is a promising nanocarrier for pancreatic cancer therapy.
- This system effectively overcomes drug insolubility and enhances anticancer efficacy.
- Further research into this novel delivery system could lead to improved cancer treatment strategies.
Related Concept Videos
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Permeability Enhancement
Cell Lines
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Self-Efficacy
Lossless Lines

